Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Dec;93(12):6588-6594.
doi: 10.1002/jmv.27214. Epub 2021 Jul 28.

Safety of COVID-19 vaccines

Qutaiba A Al Khames Aga  1 , Waseem H Alkhaffaf  2 , Tagreed H Hatem  3 , Kawthar F Nassir  3 , Yazan Batineh  1 , Abdullah T Dahham  1 , Dimah Shaban  1 , Luma A Al Khames Aga  4 , Manhal Y R Agha  5 , Muaamar Traqchi  1
Affiliations
Randomized Controlled Trial

Safety of COVID-19 vaccines

Qutaiba A Al Khames Aga et al. J Med Virol. 2021 Dec.

Abstract

This study is aimed to identify the adverse effects associated with three types of coronavirus disease 2019 vaccines. Approximately 1736 individuals agreed to participate in this study. The participants involved in the study were individuals who had received the first dose or full course (two doses) of the vaccine at least 30 days before the survey. A direct and interactive web-based system interview with a paper and electronic version of the questionnaire was used for all participants. A total of 1736 randomized individuals were identified. The reactogenicity of the vaccines including pain, redness, urticaria, and swelling at the site of the injection was reported in 34.56% of the participants. Local site reaction was reported in more individuals who had Pfizer and AstraZeneca vaccines than those who received the Sinopharm vaccine. The systemic events were more common with AstraZeneca and Pfizer vaccines, symptoms reported were fatigue, body pain, headache, muscle pain, fever, and gastrointestinal side effects. There were no correlations between age or gender, and the duration of the adverse effects for the three vaccines. Swelling and severe allergic reaction of the eyelids, severe hypotension, generalized body aches, shortness of breath, weakness and numbness on the injected arm, acute hyperglycemia, severe chest pain, and fever more than 39°C were among the unusual signs and symptoms reported by the participants. Pfizer, AstraZeneca, and Sinopharm vaccines were found to be safe and Sinopharm vaccine showed a lower prevalence of adverse effects compared with the other vaccines. The duration and severity of adverse effects were not affected by age or gender. Unusual side effects should be closely monitored to establish determine they are linked to the immunization.

Keywords: AstraZeneca vaccine; COVID-19; Pfizer vaccine; Sinopharm vaccine; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interests.

Figures

Figure 1
Figure 1
Prevalence of adverse effect reported by all participants
Figure 2
Figure 2
Prevalence of adverse effect reported by participants administered the first dose
Figure 3
Figure 3
Prevalence of adverse effect reported by participants administered the second dose
Figure 4
Figure 4
Hazard ratio associated with the three types of vaccines
See this image and copyright information in PMC

References

    1. Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID‐19 vaccine. Nature Med. 2021;27(2):225‐228. - PMC - PubMed
    1. Paltiel AD, Schwartz JL, Zheng A, Walensky RP. Clinical outcomes of a COVID‐19 vaccine: implementation over efficacy: study examines how definitions and thresholds of vaccine efficacy, coupled with different levels of implementation effectiveness and background epidemic severity, translate into outcomes. Health Aff. 2021;2020:02054‐41. 10.1377/hlthaff - DOI - PMC - PubMed
    1. Loo K‐Y, Letchumanan V, Ser H‐L, et al. COVID‐19: insights into potential vaccines. Microorganisms. 2021;9(3):605. - PMC - PubMed
    1. Aghebati‐Maleki L, Bakhshinejad B, Baradaran B, et al. Phage display as a promising approach for vaccine development. J Biomed Sci. 2016;23(1):1‐18. - PMC - PubMed
    1. Dube T, Ghosh A, Mishra J, Kompella UB, Panda JJ. Repurposed drugs, molecular vaccines, immune‐modulators, and nanotherapeutics to treat and prevent COVID‐19 associated with SARS‐CoV‐2, a deadly nanovector. Adv Ther. 2021;4(2):2000172. - PMC - PubMed

Publication types

MeSH terms